Aurodox inhibits type III secretion in multiple Gram-negative pathogens

Area of Science:

• Microbiology
• Bacterial Pathogenesis
• Drug Discovery

Background:

• Gram-negative pathogens present significant health challenges due to antibiotic resistance.
• Antivirulence (AV) compounds offer a novel strategy by targeting virulence factors instead of bacterial viability.
• Aurodox previously showed promise against the type 3 secretion system (T3SS) in E. coli.

Purpose of the Study:

• To investigate the efficacy of aurodox against the T3SS of various Gram-negative pathogens.
• To explore the conserved mechanisms of aurodox's antivirulence activity.
• To assess aurodox's potential as a therapeutic agent against bacterial infections.

Main Methods:

• Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess T3SS inhibition.
• Confocal imaging was employed to observe the effects of aurodox on infected host cells.
• Comparative transcriptomic analysis was performed on E. coli and S. Typhimurium treated with aurodox.

Main Results:

• Aurodox demonstrated inhibitory effects on the T3SS of Salmonella Typhimurium, Yersinia pseudotuberculosis, and Vibrio parahaemolyticus.
• Aurodox protected host cells from late-stage infection by blocking the SPI-2 T3SS in S. Typhimurium.
• Transcriptomic data revealed conserved gene expression changes in response to aurodox across different pathogens.

Conclusions:

• Aurodox exhibits broad-spectrum antivirulence activity against key Gram-negative pathogens by targeting their T3SS.
• The compound's mechanism of action appears conserved, suggesting potential for broader therapeutic applications.
• Further research into aurodox's mechanisms can guide the development of new anti-infective strategies.